Natera (NASDAQ:NTRA) CFO Sells $811,098.30 in Stock

October 31, 2026 by InsiderTrades.com

Key Points

Natera CFO Michael Brophy sold 1,906 shares at an average price of $425.55, generating $811,098.30. The transaction reduced his holdings by 3.93% to 46,574 shares and was executed under a pre-arranged Rule 10b5-1 plan.
Natera shares opened at $414.30, near their 52-week high of $437.41, following strong momentum and positive investor interest in its oncology testing business. The company’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while its adjusted loss per share exceeded analyst expectations.
Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $394.31, although the stock’s elevated valuation and expected quarterly loss present risks ahead of its scheduled November 5 earnings report.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 1,906 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $425.55, for a total value of $811,098.30. Following the completion of the transaction, the chief financial officer owned 46,574 shares of the company's stock, valued at $19,819,565.70. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

2 Biotech Stocks Shaping Up for Major Breakouts

Michael Burkes Brophy also recently made the following trade(s):

On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $510,755.32.
On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.
On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Stock Performance

NTRA stock opened at $414.30 on Friday. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41. The company's 50 day simple moving average is $377.06 and its 200-day simple moving average is $266.44.

3 Under-the-Radar Healthcare Companies

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the business posted ($0.74) EPS. The company's revenue was up 37.7% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Hedge Funds Weigh In On Natera

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

A number of hedge funds have recently modified their holdings of the stock. Provenance Wealth Advisors LLC acquired a new stake in Natera during the third quarter valued at $89,000. Factory Mutual Insurance Co. purchased a new position in Natera in the third quarter valued at about $491,000. Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Natera in the third quarter valued at about $6,620,000. Greenleaf Trust acquired a new position in Natera in the 3rd quarter worth about $240,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Natera in the 3rd quarter worth about $7,545,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several research analyst reports. TD Cowen increased their price objective on Natera from $340.00 to $480.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. Piper Sandler lifted their target price on Natera from $249.00 to $363.50 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Canaccord Genuity Group lifted their target price on Natera from $375.00 to $500.00 and gave the company a "buy" rating in a research note on Monday, October 19th. Guggenheim upped their target price on Natera from $360.00 to $475.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Finally, Citigroup increased their price target on shares of Natera from $365.00 to $480.00 and gave the stock a "buy" rating in a research report on Tuesday, October 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $394.31.

Check Out Our Latest Report on NTRA

Natera Company Profile

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.